Novo's performance has been fueled by an incredibly concerning trend, the growing incidence of diabetes worldwide. As the leader in insulin -- a must-have for Type 1 diabetes patients and a growing need for many Type 2 diabetics -- the company is well-positioned to capitalize on this secular trend....
FULL ARTICLE AT The Motley Fool